The third edition of “The Pharmaceutical Cannabis Report,” published by Prohibition Partners and Cannabiscientia, examines cannabis research over the past 13 years within the global pharmaceutical landscape. Analysts studied more than 400 clinical trials registered on clinicaltrials.gov from 2010 to 2023. The majority of these trials occurred in the US (54%), followed by the UK (13%), Canada (7.7%), and Israel (6.8%). Germany and Italy conducted a smaller number of trials, each accounting for 1.4% of the total. The authors note that institutional support for medical cannabis research varies by region, with slower progress in EU countries. In recent years, there has been an increase in clinical trials focused on CBD alone, which may be attributed to easier ethical committee approvals compared to trials involving controlled substances like THC. GW Pharmaceuticals is the leading company in clinical research on medicinal cannabinoids, sponsoring more trials in the past decade than the next five leading sponsors combined. The company’s dominance in clinical trials and patents can be attributed to products like Epidiolex and Sativex. GW holds a monopoly on cannabis-related patents, with a portfolio consisting of 396 patent families and 1,824 individual patents. The company continues to expand its patent portfolio rapidly, with over 320 new patents published in 2022 alone. GW’s patents cover various indications, including epilepsy, cancer, psychosis, autism spectrum disorders, inflammatory bowel disease, arthritis, and Parkinson’s disease. CBD is the most common cannabinoid in GW’s patent portfolio, but other cannabinoids like THCV, THC, CBDV, CBDA, CBG, and CBC are also frequently included. Several companies, including Hanyi Biotech, Zynerba Pharmaceuticals, Canopy Growth, Tilray, and Echo Pharmaceuticals, are emerging as significant players in cannabinoid science. GW’s market exclusivity for Epidiolex and Sativex in the US is expected to expire in the next decade, allowing for the entry of generic versions. As a result, the pharmaceutical cannabis space is likely to see increased competition and activity in clinical research.

 the third edition of “The Pharmaceutical Cannabis Report” published by Prohibition Partners and Cannabiscientia:

1. You can find the report on the Prohibition Partners website.
2. You can also find the report on the Cannabiscientia website.

GW Pharmaceuticals is the leading company in clinical research on medicinal cannabinoids, sponsoring more trials in the past decade than the next five leading sponsors combined. The company’s dominance in clinical trials and patents can be attributed to products like Epidiolex and Sativex. GW holds a monopoly on cannabis-related patents, with a portfolio consisting of 396 patent families and 1,824 individual patents. The company continues to expand its patent portfolio rapidly, with over 320 new patents published in 2022 alone. GW’s patents cover various indications, including epilepsy, cancer, psychosis, autism spectrum disorders, inflammatory bowel disease, arthritis, and Parkinson’s disease. CBD is the most common cannabinoid in GW’s patent portfolio, but other cannabinoids like THCV, THC, CBDV, CBDA, CBG, and CBC are also frequently included. Several companies, including Hanyi Biotech, Zynerba Pharmaceuticals, Canopy Growth, Tilray, and Echo Pharmaceuticals, are emerging as significant players in cannabinoid science. GW’s market exclusivity for Epidiolex and Sativex in the US is expected to expire in the near future.

Learn more:

1. prohibitionpartners.com2. prohibitionpartners.com3. cannabiscientia.com4. patents.justia.com5. patentforecast.com6. cannabishealthnews.co.uk7. prohibitionpartners.com8. jazzpharma.com9. clinicaltrialsarena.com10. clinicaltrialsarena.com11. en.wikipedia.org12. investor.jazzpharma.com13. biotech-careers.org14. cas.org15. europeanpharmaceuticalreview.com16. labmanager.com17. globenewswire.com18. businesswire.com19. frontiersin.org